[go: up one dir, main page]

WO2010019701A3 - Diaryl urea derivatives - Google Patents

Diaryl urea derivatives Download PDF

Info

Publication number
WO2010019701A3
WO2010019701A3 PCT/US2009/053595 US2009053595W WO2010019701A3 WO 2010019701 A3 WO2010019701 A3 WO 2010019701A3 US 2009053595 W US2009053595 W US 2009053595W WO 2010019701 A3 WO2010019701 A3 WO 2010019701A3
Authority
WO
WIPO (PCT)
Prior art keywords
diaryl urea
urea derivatives
derivatives
sorafenib
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/053595
Other languages
French (fr)
Other versions
WO2010019701A2 (en
Inventor
Julie Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Concert Pharmaceuticals Inc
Original Assignee
Concert Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concert Pharmaceuticals Inc filed Critical Concert Pharmaceuticals Inc
Publication of WO2010019701A2 publication Critical patent/WO2010019701A2/en
Publication of WO2010019701A3 publication Critical patent/WO2010019701A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates to novel diaryl urea compounds, their derivatives, and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel diaryl urea compounds that are derivatives of sorafenib. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering multikinase inhibitors, such as sorafenib.
PCT/US2009/053595 2008-08-14 2009-08-12 Diaryl urea derivatives Ceased WO2010019701A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18892708P 2008-08-14 2008-08-14
US61/188,927 2008-08-14
US20357808P 2008-12-23 2008-12-23
US61/203,578 2008-12-23

Publications (2)

Publication Number Publication Date
WO2010019701A2 WO2010019701A2 (en) 2010-02-18
WO2010019701A3 true WO2010019701A3 (en) 2010-08-26

Family

ID=41508104

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/053595 Ceased WO2010019701A2 (en) 2008-08-14 2009-08-12 Diaryl urea derivatives

Country Status (1)

Country Link
WO (1) WO2010019701A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10568965B2 (en) 2009-06-09 2020-02-25 Auspex Pharmaceuticals, Inc. Aminopyrimidine inhibitors of tyrosine kinase

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010135579A1 (en) * 2009-05-22 2010-11-25 Concert Pharmaceuticals, Inc. Fluorinated diaryl urea derivatives
CN102803221B (en) * 2010-03-18 2014-09-10 苏州泽璟生物制药有限公司 Deuterated ω-diphenylurea and its derivatives and pharmaceutical composition comprising the compound
WO2011113203A1 (en) * 2010-03-18 2011-09-22 苏州泽璟生物制药有限公司 Deuterium-substituted omega-diphenylurea and derivatives thereof and pharmaceutical compositions comprising the compounds
CN102190616B (en) * 2010-03-18 2015-07-29 苏州泽璟生物制药有限公司 A kind of deuterated synthesis of ω-diphenyl urea and the Method and process of production
US9145390B2 (en) 2011-03-03 2015-09-29 Concert Pharmaceuticals, Inc. Derivatives of pyrazole-substituted amino-heteroaryl compounds
CN105348186B (en) * 2015-10-15 2018-05-22 青岛海洋生物医药研究院股份有限公司 Deuterated substituted bisarylurea compound and preparation method thereof and the application in anti-tumor drug is prepared

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005009961A2 (en) * 2003-07-23 2005-02-03 Bayer Pharmaceuticals Corporation Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
WO2007059155A1 (en) * 2005-11-14 2007-05-24 Bayer Pharmaceuticals Corporation Treatment of cancers having resistance to chemotherapeutic agents
WO2007059154A2 (en) * 2005-11-14 2007-05-24 Bayer Healthcare Llc Treatment of cancers with acquired resistance to kit inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005009961A2 (en) * 2003-07-23 2005-02-03 Bayer Pharmaceuticals Corporation Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
WO2007059155A1 (en) * 2005-11-14 2007-05-24 Bayer Pharmaceuticals Corporation Treatment of cancers having resistance to chemotherapeutic agents
WO2007059154A2 (en) * 2005-11-14 2007-05-24 Bayer Healthcare Llc Treatment of cancers with acquired resistance to kit inhibitors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DUMONT ET AL: "Prospects in the use of deuterated molecules as therapeutic agents", REVUE IRE, INSTITUT NATIONAL DES RADIOELEMENTS, BELGIUM, vol. 6, no. 4, 1 January 1982 (1982-01-01), pages 2 - 10, XP009125461, ISSN: 0770-1160 *
FOSTER A B: "Deuterium isotope effects in the metabolism of drugs and xenobiotics: implications for drug design", ADVANCES IN DRUG RESEARCH, ACADEMIC PRESS, LONDON, GB, vol. 14, 1 January 1985 (1985-01-01), pages 1 - 40, XP009086953, ISSN: 0065-2490 *
KUSHNER DJ ET AL: "Pharmacological uses and perspectives of heavy water and deuterated compounds", CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, OTTAWA, ONT, CA, vol. 77, no. 2, 1 February 1999 (1999-02-01), pages 79 - 88, XP009086918 *
PLEISS, U. ET AL.: "Syntheses of [2H3, 15N], [14C]Nexavar and its labeled metabolites", JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS, vol. 49, 2006, pages 603 - 613, XP002589132, DOI: 10.1002/jlcr.1079 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10568965B2 (en) 2009-06-09 2020-02-25 Auspex Pharmaceuticals, Inc. Aminopyrimidine inhibitors of tyrosine kinase

Also Published As

Publication number Publication date
WO2010019701A2 (en) 2010-02-18

Similar Documents

Publication Publication Date Title
WO2008024439A3 (en) 4-aminoquinazoline derivatives and methods of use thereof
WO2010017545A3 (en) Triazole compounds that modulate hsp90 activity
MX349159B (en) Deuterated derivatives of ivacaftor.
WO2010032875A3 (en) Heterocyclic carboxamide compounds
WO2010108074A3 (en) Inhibitors of pi3 kinase
WO2011055944A3 (en) Methods for treating fibromyalgia syndrome
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
WO2009155121A3 (en) Inhibitors of pi3 kinase
MX361542B (en) Morphinan compounds.
WO2011055965A3 (en) Methods for treating attention-deficit/hyperactivity disorder
WO2009153665A3 (en) Inhibitors of the shiga toxins trafficking through the retrograde pathway
WO2007056244A3 (en) Methods of using saha and erlotinib for treating cancer
WO2010019701A3 (en) Diaryl urea derivatives
WO2012015986A3 (en) Substituted dioxopiperidinyl phthalimide derivatives
HK1201828A1 (en) Treatment regimens using multiple pharmaceutical agents
EA201390428A1 (en) COMPOSITIONS AND METHODS OF TREATMENT OF PULMONARY HYPERTENSION
WO2012002687A3 (en) Methods for treating bipolar disorder
IL193252A0 (en) N-hydroxyacrylamide compounds
WO2009061374A3 (en) Deuterated fingolimod
WO2012054535A3 (en) Compounds, compositions and methods useful for cholesterol mobilisation
CA2881554C (en) Methods for inhibiting fascin
WO2008057456A3 (en) Methods of using saha and bortezomib for treating multiple myeloma
WO2013055913A3 (en) Pgam1 inhibitors and methods related thereto
WO2010005585A3 (en) 4-aminoquinazoline prodrugs
WO2012119006A3 (en) Derivatives of pyrazole-substituted amino-heteroaryl compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09791438

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09791438

Country of ref document: EP

Kind code of ref document: A2